A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (REVEAL)

AbbVie

Status: Suspended

Conditions: Chronic Lymphocytic Leukemia (CLL)

Study type: Observational

Funder types: Industry

Identifiers

NCT03659669

P19-287

Details and patient eligibility

About

This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).

Enrollment: 272 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
• Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
• Participants who have been informed verbally and in writing about this study, and who do not object to their data being processed or subjected to data quality control.

Exclusion criteria

• Participants currently participating (or previously participated) in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Trial design

272 participants in 1 patient group

Patients with Chronic Lymphocytic Leukemia (CLL)

Description:

Patients with diagnosed CLL and eligible to venetoclax as per label.